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Background: Caloric restriction and n-3 polyunsaturated fatty acid (PUFA) 40 
supplementation protect from some of the metabolic complications. The aim of this 41 
study was to assess the influence of a low calorie diet with or without n-3 PUFA 42 
supplementation on glucose dependent insulinotropic polypeptide (GIP) output and 43 
insulin sensitivity markers in obese subjects.  44 
Methods: Obese, non-diabetic subjects (BMI 30-40 kg/m2 and aged 25-65 yr) were 45 
put on low calorie diet (1200-1500 kcal/day) supplemented with either 1.8 g/day n-3 46 
PUFA (DHA/EPA, 5:1) (n=24)) or placebo capsules (n=24) for three months in a 47 
randomized placebo controlled trial. Insulin resistance markers and GIP levels were 48 
analyzed from samples obtained at fasting and during an oral glucose tolerance test 49 
(OGTT).  50 
Results: Caloric restriction with n-3 PUFA led to a decrease of insulin resistance 51 
index (HOMA-IR) and a significant reduction of insulin output as well as decreased 52 
GIP secretion during the OGTT. These effects were not seen with caloric restriction 53 
alone. Changes in GIP output were inversely associated with changes in red blood 54 
cell EPA content whereas fasting GIP level positively correlated with HOMA-IR index. 55 
Blood triglyceride level  was lowered by caloric restriction with a greater effect when 56 
n-3 PUFA were included and correlated positively with fasting GIP level.  57 
Conclusions: Three months of caloric restriction with DHA+EPA supplementation 58 
exerts beneficial effects on insulin resistance, GIP and triglycerides.  59 
General Significance: Combining caloric restriction and n-3 PUFA improves insulin 60 
sensitivity, which may be related to a decrease of GIP levels. 61 
This trial was registered at isrctn.com as ISRCTN11445521. 62 
 63 
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1. Introduction 68 
Obesity and its associated disorders (impaired insulin sensitivity, 69 
hyperinsulinemia, dyslipidemia, hypertension) often lead to type 2 diabetes with 70 
increased risk for cardiovascular disease [1-3]. Obesity contributes to type 2 diabetes 71 
development by affecting glucose and lipid homeostasis, which depends on the 72 
balance between insulin sensitivity and insulin secretion [4]. Incretins account for 50-73 
70% of insulin secretion after meals or an oral glucose load [5]. Glucose-dependent 74 
insulinotropic polypeptide (GIP) is released from enteroendocrine K cells in response 75 
to oral ingestion of fat or glucose [6] and stimulates insulin secretion from pancreatic 76 
β-cells in a glucose-dependent manner [7]. Transduction of its biological effects 77 
involves stimulation of G protein-coupled receptors (GPCR) [8], for example GPR 78 
120 [9].  79 
 Adequate insulin sensitivity and insulin secretion can be restored by achieving 80 
appropriate body mass through adopting a healthy diet, energy restriction, and 81 
physical activity [10-11]. A diet rich in omega-3 (n-3) polyunsaturated fatty acids 82 
(PUFA) reduces risk for obesity complications by influencing lipid metabolism, 83 
inflammation, coagulation and atherogenesis [12-14]. Increasing intake of n-3 fatty 84 
acids leads to changes in cell membrane phospholipid fatty acid composition, which 85 
affects cell and tissue function through alterations in the properties of membranes, 86 
altered cell signaling pathways, and modified gene expression profiles [15-18]. 87 
Docosahexaenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3) are 88 
considered the most biologically active n-3 PUFA [19-20].  89 
 Beneficial effects of n-3 PUFA on glucose homeostasis have been 90 
documented in animal models of obesity and metabolic syndrome [21-22]. 91 
Improvement in glucose tolerance after n-3 PUFA supplementation in obese humans 92 
has been less frequently reported and seems to be related to the presence of obesity 93 
complications [23-26]. Whether GIP is involved in the effect of n-3 PUFA on the 94 
insulin response to a glucose load has not been reported in human studies. Thus, it is 95 
not clear if n-3 PUFA affect the incretin system in humans with obesity and 96 
prediabetes.  97 
 The aim of this study was to investigate the effects of caloric restriction with or 98 
without consumption of n-3 PUFA (DHA+EPA) on GIP, insulin release and metabolic 99 














2. Materials and Methods 101 
 102 
2.1. Subjects 103 
 Obese subjects (BMI 30-40 kg/m2) aged 25-65 years were recruited from the 104 
Out-Patient Clinic of Obesity and Lipid Disorders and the Department of Metabolic 105 
Disorders, Jagiellonian University Medical College, Krakow, Poland. Exclusion 106 
criteria included: diabetes or other endocrine disorders, chronic inflammatory 107 
diseases, and kidney or liver dysfunction. Subjects participating in the study had not 108 
taken lipid-lowering or anti-inflammatory drugs or supplements containing vitamins A, 109 
C, or E, β-carotene or PUFA. Fish consumption was not allowed during the study 110 
period.  111 
 112 
2.2. Study design and intervention 113 
This clinical trial was randomized, double-blind placebo-controlled parallel and 114 
single center. The trial was carried out in accordance with The Code of Ethics of the 115 
World Medical Association (Declaration of Helsinki) and with the Good Clinical 116 
Practice guidelines. The trial was approved by Bioethics Committee of the 117 
Jagiellonian University in Cracow (written consent, opinion No. KBET/82/B/2009) and 118 
all subjects gave written informed consent. The trial was conducted at the 119 
Department of Clinical Biochemistry, Jagiellonian University, Medical College, 120 
Krakow, Poland. The trial was registered at isrctn.com as ISRCTN11445521. 121 
 Recruited subjects were randomly assigned to the n-3 PUFA or the placebo 122 
group by using minimalization software balanced for age and sex. 123 
 Obese subjects (BMI 30 - 40 kg/m2) underwent an adaptation period of two 124 
weeks. During this time they were advised by a dietician on how to apply an 125 
isocaloric diet containing 2300-2400 kcal/d according to individual caloric 126 
requirement. The diet contained 57% of energy from carbohydrates, 30% from fat 127 
and 13% from protein. After the adaptation period, subjects were advised to use a 128 
low calorie diet. The caloric value of the low calorie diet was 1200 kcal/d for women 129 
and 1500 kcal/d for men and 60% of energy was provided from carbohydrates (with 130 
low glycemic index), 15% from protein and 25% from fat. Subjects were randomly 131 
assigned to receive placebo (corn oil) capsules (CR placebo) or n-3 PUFA (EPAX 132 














for 3 months. Three n-3 PUFA capsules contained 1.8 g DHA+EPA in a ratio of 5:1. 134 
Both capsule types were identical in size, shape and appearance and contained 4 mg 135 
of vitamin E per capsule. Subjects were advised to swallow their capsules after a 136 
meal. 137 
 All subjects were given written and verbal instructions by a dietician about the 138 
preparation of a caloric restricted diet and consumption of capsules. Body 139 
composition changes including fat content, muscle mass and water content were 140 
measured by Tanita Body Composition Analyzer BC-418 (Tanita, Japan). Hip and 141 
waist circumferences, diet and supplementation compliance, and nutritional habits 142 
were assessed. 143 
Anthropometric measurements (BMI, hip and waist circumference, systolic and 144 
diastolic blood pressure, adipose tissue content) were performed at baseline (after 145 
the two week adaptation period) and at the end of three months intervention and after 146 
a 12 hr overnight fast. An oral glucose tolerance test (OGTT; 75 g glucose load) was 147 
performed according to WHO guidelines. At fasting and every 30 min up to 2 h 148 
venous blood was collected for measurement of serum glucose, insulin, GIP, non-149 
esterified fatty acids (NEFA), total cholesterol, HDL cholesterol and triglycerides. 150 
Additionally, at fasting baseline and at the end of treatment venous blood was 151 
collected for determination of plasma phosphatidylcholine (PC) composition and fatty 152 
acid content of erythrocytes’ membranes (see below). All samples were centrifuged 153 
at 1000 x g for 15 min at 4C. Serum, plasma and erythrocytes’ samples were 154 
aliquoted and stored at -80C until analysis. Sample size was calculated to 25 per 155 
group to detect a 50% change in insulin sensitivity markers at a P value <0.05 with a 156 
power of 80%. 157 
 158 
2.3. Compliance  159 
Counting the number of returned capsules during the follow up visits was used 160 
to assess compliance to capsules intake. In addition, the fatty acid composition of 161 
plasma phosphatidylcholine (PC), and of erythrocytes (RBC) was determined by gas 162 
chromatography using methods described previously [27].  163 
Because of concerns about compliance to n-3 PUFA capsules in the n-3 PUFA 164 
group and contamination in the placebo group (i.e. intake of n-3 PUFA capsules) it 165 
was decided before hand to use a cut-off of a 20% increase in “omega-3 index”, the 166 














violators in the placebo group. Using the threshold of a 20% increase in omega-3 168 
index resulted in retention of data for 24 subjects in the n-3 PUFA group and 24 169 
subjects in the placebo group.  170 
 171 
2.4. Biochemical measurements 172 
Subjects were instructed to avoid strenuous exercise and alcohol consumption 173 
the day before blood collection. Plasma glucose, total cholesterol, HDL-cholesterol 174 
and triglycerides were assayed by automated, enzymatic colorimetric methods 175 
(ELITech Clinical Systems, France). The intra and inter-assay variability coefficients 176 
were as follows: 2.3% and 3.5% (glucose), 1.4% and 3.4% (triglycerides), 1.4% and 177 
3.8% (total cholesterol), 2.1% and 2.8% (HDL-cholesterol), respectively. LDL-178 
cholesterol was calculated from measured values of total cholesterol, triglycerides 179 
and HDL-cholesterol according to the Friedewald formula.  180 
Non esterified fatty acids (NEFA) concentration was measured immediately in 181 
non-frozen plasma by enzymatic quantitative colorimetric method (Roche Diagnostics 182 
GmbH, Germany). 183 
Insulin was determined by an immunoradiometric method (DIAsource 184 
ImmunoAssays, Belgium) and read using a gamma counter (LKB Instruments). 185 
Within and between-run imprecision CVs were 2.1% and 6.5%, respectively.  186 
GIP was measured using ELISA (EMD Millipore, St Charles, MO, USA). Within-run 187 
CV was 6.1% and between-run CV 8.8%. The limit of detection was 8.2 pg/ml.  188 
 189 
2.5. Presentation of results  190 
Area under concentration time curve (AUC) for glucose, insulin, GIP, 191 
triglycerides and NEFA during the OGTT was calculated by the trapezoidal method 192 
[28]. Β-cell function was assessed by the ratio of the insulin to glucose AUC 193 
(AUCI/AUCG) and the insulinogenic index (IGI). IGI is a measure of first-phase insulin 194 
secretion [29] and was calculated as the ratio of the difference between the post oral 195 
glucose load insulin peak (at 60 min) and basal insulin to the difference in glucose 196 














model assessment (HOMA-IR) [30]. Post oral glucose load insulin sensitivity was 198 
determined using an oral glucose insulin sensitivity index (OGIS) proposed by Mari et 199 
al. [31] which can be computed using a calculator for Excel spread sheet available on 200 
the webpage http://webmet.pd.cnr.it/ogis .  201 
 202 
2.6. Statistical analysis 203 
Only responders were included in the analysis (n=24 in the n-3 PUFA group 204 
and n=24 in the placebo group). The Kolmogorov-Smirnov test was used to test the 205 
data for a Gaussian distribution. Normally distributed data are presented as mean ± 206 
SEM, otherwise as median and interquartile range (IQR). Between group differences 207 
were analysed by unpaired t test or non-parametric U-Mann Whitney test. Continuous 208 
variables obtained before and after the treatment were log transformed if required 209 
and analysed by paired t test (non-normally distributed data were analysed by 210 
Wilcoxon’s test) to identify treatment-induced differences between individual groups. 211 
Spearman rank correlation was used to assess relationship between variables. All 212 
analyses were performed with Statistica software (StatSoft). A P value < 0.05 was 213 
considered statistically significant.  214 
 215 
3. Results 216 
  217 
3.1. Study population, intervention and basal characteristics of subjects  218 
This trial aimed to investigate the effect of n-3 PUFA supplementation on 219 
insulin sensitivity markers in obese nondiabetic subjects on a calorie restricted diet. 220 
The recruitment of obese study participants began in September 2009 and was 221 
completed in July 2013.  222 
Eighty-five of 195 screened obese subjects were enrolled in the study and 223 
randomly assigned to n-3 PUFA or placebo treatment. The progression of subjects 224 
through the study is shown in Figure 1. Three subjects were lost to follow-up (2 in the 225 
n-3 PUFA group and 1 in the placebo group).  After randomization, 2 subjects were 226 
excluded (1 from the n-3 PUFA group and 1 from the placebo group) because they 227 
were newly diagnosed with type 2 diabetes during the 2-h OGTT. Six subjects 228 
declined to participate after allocation to intervention groups: one from the placebo 229 














Six subjects were excluded during the follow-up period. Three subjects from the 231 
placebo group discontinued intervention: 1 woman due to pregnancy and 2 subjects 232 
got new work outside the country. From the n-3 PUFA group 3 subjects were 233 
excluded: one subject claimed that taking capsules leads to weight gain, 1 subject 234 
developed pneumonia that required hospitalization and 1 subject required 235 
hospitalization for decompensation of preexisting heart failure. The n-3 PUFA 236 
capsules were safe and well tolerated. No adverse effects were observed after 237 
DHA/EPA (5:1) supplementation except one subject who claimed that taking these 238 
capsules contributes to weight gain. Finally, 36 patients in placebo group and 32 239 
patients in n-3 PUFA group completed the trial. Twenty subjects were excluded from 240 
analysis due to not meeting compliance criteria: 12 subjects from the placebo group 241 
(omega-3 index after supplementation increased more than 20%) and 8 subjects 242 
from the n-3 PUFA group (increase in omega-3 index was less than 20% after 243 
supplementation). Thus, full analyses were performed in 48 subjects: 24 in the 244 
placebo group and 24 in the n-3 PUFA group. Baseline characteristics did not differ 245 
between CR placebo and n-3 PUFA (CR+n-3) groups (Table 1). Subjects were mainly 246 
women (approximately 80%) with a mean age of 48 years, moderately obese (BMI: 247 
34.7  0.5 kg/m2) and without hypertension. The low value of baseline omega-3 fatty 248 
acid index (5.63  0.19%) is consistent with the selection of subjects with low fish 249 
intake. Subjects had slightly elevated total and LDL cholesterol concentrations 250 
although plasma triglyceride concentrations were not elevated (Table 1). Fasting 251 
blood glucose concentration was normal but plasma insulin concentration was 252 
slightly increased (Table 1).  253 
 254 
3.2. Anthropometric measurements and lipid parameters after intervention  255 
  After the 3 month intervention period, subjects in the CR+n-3 group had higher 256 
levels of EPA and DHA in plasma phosphatidylcholine (PC) (average 55% and 80% 257 
increase over baseline, respectively) and in erythrocytes (average 80% and 63% 258 
increase over baseline, respectively), as well as mean 66% increase in the omega-3 259 
index compared to baseline (9.01 ± 0.36 vs 5.41 ± 0.25 % ; P<0.0001) (Table 2). In 260 
the CR placebo group the level of n-3 PUFA in RBC and omega-3 index did not 261 
change, although a decrease in plasma PC EPA, but not DHA, was observed 262 














Caloric restriction led to an approximately 8% decrease (p<0.0001) of body 264 
weight and adipose tissue mass in both groups, without any statistically significant 265 
differences between groups (Table 2). The CR placebo group showed a 17% 266 
decrease in fasting TG concentration as well as a 16% decrease in TG AUC during 267 
OGTT (Table 2). This effect was greater and more significant in subjects also 268 
supplemented with n-3 PUFA (CR+n-3 group) whose decrease in fasting TG 269 
concentration and TG AUC during OGTT was approximately 30% below baseline 270 
(P=0.0003) (Table 2). Neither caloric restriction nor n-3 PUFA influenced fasting 271 
NEFA or NEFA level during OGTT (Table 2). No changes in plasma total, HDL and 272 
LDL cholesterol levels were observed after 3 months of caloric restriction with either 273 
placebo (CR placebo) or n-3 PUFA (CR+n-3) (Table 2).  274 
 275 
3.3. Changes in the GIP level and insulin sensitivity markers after intervention 276 
Three months of caloric restriction alone (CR placebo), or in combination with 277 
n-3 PUFA (CR+n-3) had no significant affect on the fasting glucose concentration or 278 
glucose AUC during OGTT (Table 2). Caloric restriction in combination with n-3 PUFA 279 
decreased fasting (Table 2) and 60’ OGTT insulin levels (98.81  10.23 vs 128.53  280 
14.04 IU/ml, P<0.05). The insulin OGTT AUC was also significantly decreased 281 
(P<0.05) (Table 2). These measurements were not affected by caloric restriction 282 
alone. Fasting blood GIP level was lowered in the CR+n-3 group (P<0.05) (Table 2) 283 
and a 30% decrease of the GIP AUC from baseline was observed (P<0.01) (Table 2). 284 
In contrast, caloric restriction alone (without n-3 PUFA supplementation) did not affect 285 
GIP level at fasting or during the OGTT (Table 2).  286 
 In the whole group of subjects (n=48) changes in GIP AUC were inversely 287 
correlated with changes in erythrocyte EPA content (rho= -0.37; P=0.009) (Table 3). 288 
After 3 months of intervention fasting plasma GIP level correlated positively with 289 
fasting plasma TG level and TG AUC during OGTT (rho=0.4; P=0.004) in the CR+n-3 290 
group (Table 3). 291 
  The ratio of insulin to glucose areas under the curve (AUCI/AUCG) (which 292 
reflects the secretory ability of β cells [29]) was significantly decreased in the CR+n-3 293 
group (P=0.02), but not in the group receiving only calorie restriction (Table 2). The 294 
insulinogenic index (IGI=∆I0-60/∆G0-60), which measures first phase insulin secretion, 295 
and the oral glucose insulin sensitivity index (OGIS) were not significantly changed in 296 














 A significant (P=0.01) decrease (by 20%) in insulin resistance measured by 298 
HOMA-IR index was observed in the CR n-3 group, with no effect in the CR placebo 299 
group (Table 2). After intervention the HOMA-IR index was positively correlated with 300 
fasting plasma GIP level (rho=0.29; P=0.04) in the CR n-3 group (Table 3). 301 
 302 
4. Discussion 303 
The study confirms that controlled caloric restriction leads to loss of body 304 
weight, fat mass and BMI and shows no additional effect of n-3 PUFA on these 305 
measures. The main new findings of the study are that combining caloric restriction 306 
with 1.8 g/day of DHA+EPA (in a ratio of 5:1) improves insulin sensitivity, which was 307 
not seen with caloric restriction alone, and causes a greater lowering of plasma 308 
triglyceride concentration than seen with caloric restriction alone. The subjects 309 
studied were obese and without diabetes but with slightly elevated fasting plasma 310 
insulin level as well as total and LDL cholesterol concentrations. The finding of 311 
improved insulin sensitivity with n-3 PUFA is important since it suggests an improved 312 
metabolic function and a possible lowering of risk for future cardiometabolic 313 
complications. The beneficial metabolic changes induced by n-3 PUFA in individuals 314 
with caloric restriction correlated with a lower output of GIP. 315 
It is well known that a decrease in body weight in obese persons will per se 316 
influence glucose and lipid metabolism, decreasing the risk for cardiovascular 317 
complications  [32]. Similarly, marine n-3 PUFA supplementation is reported as a 318 
protective factor against dyslipidemia and atherosclerosis  [15, 33-34]. Several 319 
studies suggest that DHA/EPA can contribute to additional weight loss in calorie 320 
restricted individuals; this would obviously be a major health benefit. For example, 321 
Thorsdottir et al. reported a greater decrease in body weight after 8 weeks of caloric 322 
restriction combined with 1.3 g/day EPA+DHA in comparison to placebo in obese 323 
adults [11]. However, the current study did not observe any additional effect of 1.8 g/d 324 
DHA+EPA supplementation for three months on weight loss and body adipose tissue 325 
content compared with what was observed with caloric restriction alone. Subjects 326 
participating in the current study did not undertake any specific physical activity 327 
regimen and the diet they used was less restricted in comparison to that of 328 
Thorsdottir et al.  [11].  Similarly to the findings of our study, Munro and Garg 329 














metabolic profile but did not modify weight of obese patients on a calorie restricted 331 
diet  [35]. 332 
 This study demonstrated that in combination with caloric restriction DHA+EPA 333 
supplementation decreases GIP output, improves insulin sensitivity, and lowers 334 
plasma triglyceride level. It is widely reported that n-3 PUFA at a dose of 3-4 g/day 335 
can lower fasting plasma triglycerides by 25 to 50% [36]. The current study 336 
demonstrates that calorie restricted obese subjects supplemented with a more 337 
moderate dose of DHA+EPA (1.8 g/day) for 3 months show  decreases in plasma 338 
fasting triglycerides comparable with these findings. Furthermore, we found that n-3 339 
PUFA decrease the triglyceride response seen during an OGTT. This would suggest 340 
an improved clearance of triglycerides from the circulation, perhaps due to improved 341 
insulin sensitivity. However, we did not observe any effect of n-3 PUFA on total, LDL 342 
or HDL cholesterol concentrations. This finding is in agreement with studies by 343 
Schuchardt et al. who demonstrated an increase in omega-3 index of more than 4% 344 
after 6 months of 1.68 g/day n-3 PUFA which also caused a significant decrease in 345 
plasma triglycerides but not in other risk factors of atherosclerosis such as total and 346 
LDL cholesterol concentrations [37].  347 
Marine fish intake has been documented to be associated with improved 348 
glucose homeostasis. For example, Feskens et al. showed that higher intake of 349 
marine fish was associated with lowered relative risk of impaired glucose tolerance  350 
[38]. Other studies showed a negative association between fish intake and the risk for 351 
type 2 diabetes [39-41]. These effects of fish may be due to n-3 PUFA. However, less 352 
favorable effects on glucose control were sometimes observed in subjects 353 
supplemented with more than 3 g/day of n-3 PUFA [26, 42, 43].  Our results 354 
demonstrated that n-3 PUFA did not affect fasting glucose but lowered fasting insulin 355 
and decreased basal insulin resistance index (HOMA-IR), which suggests a reduction 356 
of (mainly) hepatic insulin resistance  [44-45]. It has been reported that three months 357 
of a low fat diet enriched with n-3 PUFA in subjects with metabolic syndrome 358 
decreased insulin resistance and improved insulin signalling in subcutaneous white 359 
adipose tissue [46]. Improved insulin sensitivity could be related to a reduction of 360 
post oral glucose load lipaemia or to anti-inflammatory effects of n-3 PUFA [47-48]. 361 
We did not observe statistically significant changes in first phase insulin secretion 362 














  In our study the combination of 1.8 g/d of n-3 PUFA and calorie restriction, but 364 
not calorie restriction itself, resulted in a decrease in GIP concentration in the fasting 365 
state and during oral glucose load in obese patients. Decreased GIP could contribute 366 
to the observed decrease of β-cell function index measured by post oral glucose load 367 
insulin secretion (AUCINS/AUCGLUCOSE). Several studies report that β-cell secretion is 368 
sensitive to the degree of unsaturation of fatty acids [49]. We observed that changes 369 
in serum GIP levels were inversely correlated with changes in erythrocyte EPA and 370 
that fasting GIP levels were positively correlated with insulin resistance index 371 
(HOMA-IR). These observations suggest that n-3 PUFA treatment improves insulin 372 
sensitivity by lowering GIP level. As a consequence of lower GIP signalling, oxidation 373 
of fat is induced, which leads to clearing triglycerides from liver and muscles, 374 
suppression of hepatic glucose output and improvement in insulin sensitivity. Studies 375 
in animal models are consistent with this. Flachs et al. suggested that in mice fed 376 
with a high fat diet, supplementation with DHA+EPA (30 g/kg of diet) could normalize 377 
elevated GIP levels and contribute to an increase in whole body insulin sensitivity 378 
[50]. It was also reported that reduction of GIP secretion, by deletion of the GIP gene 379 
in mice, reduced insulin secretion and lessened the degree of insulin resistance with 380 
high fat feeding without changing glucose levels during OGTT [51].  381 
Several studies report that plasma GIP is elevated in obesity and metabolic 382 
syndrome [52-53] and in subjects with impaired glucose tolerance [54-56]. 383 
Interestingly, it was also reported that GIP/GIP receptor signalling was disrupted in 384 
type-2 diabetes and this could contribute to elevated GIP secretion. Hyperglycemia 385 
per se led to down-regulation of GIP receptor expression. As a consequence, insulin 386 
response to GIP was markedly reduced in islets, which resulted in the deterioration of 387 
β-cell function found in diabetes. Therefore, normalisation of GIP/GIP receptor 388 
signalling has been suggested as a potential target in the treatment of obesity-389 
associated type 2 diabetes  [57]. Results of this study also argue for the suggestion 390 
that an inhibition of GIP signalling is beneficial in insulin resistance. In diabetic 391 
patients with β-cell dysfunction as a result of lipo- and glucotoxicity, normalising of 392 
GIP/GIP receptor signalling could improve β-cell function and thus glucose 393 
homeostasis.  394 
In vitro studies demonstrated that GIP influences lipid metabolism in 395 
adipocytes from rodents [58] and humans [59] modifying lipogenesis  [60] and 396 














fasting GIP and triglyceride level  (fasting and post oral glucose load)  [64]. In this 398 
study we have also observed that after intervention with calorie restriction, higher 399 
fasting GIP levels were related to higher fasting and post oral glucose load 400 
triglyceride levels.  401 
 402 
5. Conclusions  403 
The current study suggests that providing n-3 PUFA to obese subjects 404 
undergoing caloric restriction results in beneficial effects on insulin sensitivity, which 405 
may be related to a decrease of plasma GIP levels. These findings require 406 
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Age [y] 47 ± 2
2
 48 ± 2 45 ± 2 0.47 
Sex, female [n] 38 20 18   
EPA in plasma PC [weight%] 2.22 ± 0.22 2.27 ± 0.28 2.16 ± 0.35 0.82 
DHA in plasma PC [weight%] 3.68 ± 0.22 3.72 ± 0.33 3.62 ± 0.27 0.82 
EPA in RBC membranes [%] 1.12 ± 0.06 1.19 ± 0.08 1.05 ± 0.07 0.22 
DHA in RBC membranes [%] 4.51 ± 0.15 4.65 ± 0.22 4.36 ± 0.19 0.32 
Omega-3 index [%] 5.63 ± 0.19 5.85 ± 0.28 5.41 ± 0.25 0.25 
Anthropometric measurements:         
Weight [kg] 96.18 ± 1.67 97.56 ± 2.12 94.78 ± 2.59 0.41 
BMI [kg/m
2
] 34.75 ± 0.51 35.24 ± 0.72 34.25 ± 0.7 0.33 
Waist to hip ratio 0.85 (0.82, 0.93)
3
 0.90 (0.84, 0.95) 0.83 (0.80, 0.91) 0.10 
Adipose tissue mass [%] 39.68 ± 0.91 40.7 ± 1.16 38.74 ± 1.33 0.28 
Systolic BP [mm Hg] 128.40 ± 2.49 132.5 ± 4.08 124.09 ± 2.07 0.09 
Diastolic BP [mm Hg] 84.30 ± 1.39 85.4 ± 2.4 83.14 ± 1.06 0.42 
Metabolic measurements:         
Total cholesterol [mmol/l] 5.51 ± 0.16 5.56 ± 0.28 5.45 ± 0.16 0.72 
HDL cholesterol [mmol/l] 1.31 ± 0.04 1.38 ± 0.06 1.23 ± 0.04 0.06 
LDL cholesterol [mmol/l] 3.53 ± 0.13 3.52 ± 0.21 3.53 ± 0.16 0.99 
Fasting NEFA [mmol/l] 0.77 ± 0.04 0.8 ± 0.05 0.74 ± 0.06 0.48 
AUC NEFA [mmol/l x min
-1
] 166.59 ± 11.15 180.13 ± 16.55 153.05 ± 14.75 0.23 
Fasting Triglycerides [mmol/l] 1.38 ± 0.09 1.34 ± 0.13 1.4 ± 0.13 0.77 
AUC Triglycerides [mmol/l x min
-1
] 641.75 ± 43.63 611.62 ± 58.16 671.87 ± 65.7 0.50 
Fasting glucose [mmol/l] 5.15 ± 0.09 5.1 ± 0.13 5.19 ± 0.13 0.62 
AUC Glucose [mmol/l x min
-1
] 3467.88 ± 113.80 3613 ± 162.58 3322.75 ± 157.03 0.21 
Fasting insulin [mIU/ml] 16.65 ± 1.18 17.65 ± 1.94 15.64 ± 1.35 0.40 









Fasting GIP [pg/ml] 30.15 ± 2.25 30.88 ± 3.54 29.41 ± 2.86 0.75 









Insulin resistance and β cell function:         
HOMA-IR 3.88 ± 0.31 4.11 ± 0.51 3.65 ± 0.34 0.46 
AUCI/AUCG 13.37 ± 1.07 13.36 ± 1.46 13.25 ± 1.58 0.96 






384.93 ± 9.99 379.66 ± 14.25 390.18 ± 14.21 0.60 
1
Comparison between placebo and n-3 PUFA groups (unpaired t test or Mann-Whitney U test for non-629 
normally distributed variables). 630 
2
Mean ± SEM (all such values) 631 
3
Median; IQR in parentheses (all such values) 632 
AUC, area under curve during OGTT; BP, blood pressure; BMI, body mass index; EPA, 633 
eicosapentaenoic acid; DHA, docosahexaenoic acid; GIP, glucose dependent insulinotropic 634 
polypeptide; IGI, insulinogenic index; NEFA, non esterified fatty acids; OGIS, oral glucose insulin 635 















Table 2. Anthropometric and metabolic variables at baseline and at the end of the 638 
study in subjects undergoing caloric restriction and supplemented with placebo or n-3 639 
PUFA capsules 640 











Age [y] 48 ± 2
2
     45 ± 2     
Sex, female [n] 20     18     
EPA in plasmaPC 
[weight%] 2.27 ± 0.28 1.92 ± 0.21* 0.02 2.16 ± 0.35 3.34 ± 0.54**
, #
 0.001 
 DHA in plasma PC 
[weight%] 3.72 ± 0.33 3.81 ± 0.36 0.62 3.62 ± 0.27 6.47 ± 0.47***
, #
 <0.0001 
EPA in RBC 





DHA in RBC 









measurements:             
Weight [kg] 97.56 ± 2.12 89.74 ± 2.38*** <0.0001 94.78 ± 2.59 87.93 ± 2.42*** <0.0001 
BMI [kg/m
2
] 35.24 ± 0.72 32.44 ± 0.86*** <0.0001 34.25 ± 0.7 31.66 ± 0.70*** <0.0001 
Waist to hip ratio 0.90 (0.84, 0.95)
3
 0.86 (0.83, 0.91)* 0.03 0.83 (0.80, 0.91) 0.88 (0.80, 0.92) 0.46 
Adipose tissue mass 
[%] 40.7 ± 1.16 37.45 ± 1.46*** 0.0001 38.74 ± 1.33 35.48 ± 1.67*** 0.0004 
Metabolic 
measurements:             
Total cholesterol 
[mmol/l] 5.56 ± 0.28 5.33 ± 0.25 0.28 5.45 ± 0.16 5.20 ± 0.21 0.08 
HDL cholesterol 




[mmol/l] 3.52 ± 0.21 3.34 ± 0.21 0.26 3.53 ± 0.16 3.40 ± 0.18 0.30 
Fasting NEFA 
[mmol/l] 0.8 ± 0.05 0.8 ± 0.07 0.99 0.74 ± 0.06 0.72 ± 0.06 0.83 
AUC NEFA [mmol/l x 
min
-1
] 180.13 ± 16.55 196.67 ± 19.50 0.33 153.05 ± 14.75 158.35 ± 13.21 0.78 
Fasting Triglycerides 




] 611.62 ± 58.16 510.52 ± 40.16* 0.02 671.87 ± 65.7 461.85 ± 40.81*** 0.0003 
Fasting glucose 
[mmol/l] 5.1 ± 0.13 5.16 ± 0.11 0.54 5.19 ± 0.13 5.08 ± 0.07 0.39 
AUC Glucose [mmol/l 
x min
-1
] 3613 ± 162.58 3468.25 ± 176.61 0.30 3322.75 ± 157.03 3215.5 ± 132.02 0.42 
Fasting insulin 
[mIU/ml] 17.65 ± 1.94 15.32 ± 1.72 0.10 15.64 ± 1.35 12.7 ± 1.02* 0.01 












Fasting GIP [pg/ml] 30.88 ± 3.54 30.36 ± 5.38 0.91 29.41 ± 2.86 20.67 ± 2.24* 0.02 













and β cell function:             
HOMA-IR 4.11 ± 0.51 3.59 ± 0.43 0.19 3.65 ± 0.34 2.89 ± 0.25* 0.01 
AUCI/AUCG 13.36 ± 1.46 11.72 ± 1.25 0.08 13.25 ± 1.58 11.22 ± 1.17* 0.02 






379.66 ± 14.25 383.12 ± 17.65 0.78 390.18 ± 14.21 404.38 ± 13.60 0.30 
*Significantly different between baseline and after supplementation within a group (paired t test or Wilcoxon’s test for non-641 
normally distributed variables)  642 
#
Significantly different between placebo and n-3 PUFA groups after supplementation (unpaired t test) p < 0.05  643 
1















Mean ± SEM (all such values) 645 
3
Median; IQR in parentheses (all such values) 646 
AUC, area under curve during OGTT; BP, blood pressure; BMI, body mass index; EPA, eicosapentaenoic acid; DHA, 647 
docosahexaenoic acid; GIP, glucose dependent insulinotropic polypeptide; IGI, insulinogenic index; NEFA, non esterified fatty 648 



















Table 3. Spearman rank correlation between changes in variables (∆) during 3 655 





∆GIP AUC & ∆EPA RBC 
-0.37 0.009 
Fasting GIP & Fasting TG  
0.40 0.004 
Fasting GIP & TG AUC 
0.41 0.004 




Statistically significant correlations, P < 0.05 658 
GIP, glucose dependent insulinotropic polypeptide; AUC, area under curve during OGTT; EPA, 659 














Figure legends 661 
 662 





































1. Caloric restricted diet with n-3 PUFA improves insulin sensitivity in obese subjects  674 
 675 
2. n-3 PUFA supplementation combined with low calorie diet decrease GIP output 676 
 677 
3. Blood triglycerides reduced after caloric restriction diet combined with n-3 PUFA 678 
 679 
4. GIP level was positively correlated with HOMA-IR index and triglycerides 680 
